RECURSION PHARMACEUTICALS, INC. Deferred Foreign Income Tax Expense (Benefit)
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Deferred Foreign Income Tax Expense (Benefit) of -$55.69 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2025 was -$55.69M.
- RECURSION PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2024 was -$9.92M.
- RECURSION PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2023 was -$4.56M.
- RECURSION PHARMACEUTICALS, INC. deferred foreign income tax expense (benefit) for fiscal 2022 was -$471.00K.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month | Deferred Foreign Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$55.69M 10-K · filed 2026-02-25 | |
| 2024-12-31 | -$9.92M 10-K · filed 2026-02-25 | |
| 2023-12-31 | -$4.56M 10-K · filed 2026-02-25 | |
| 2022-12-31 | -$471.00K 10-K · filed 2025-02-28 | $471.00K 10-K · filed 2023-02-27 |
| 2021-12-31 | -$149.00K 10-K · filed 2024-02-29 | $149.00K 10-K · filed 2023-02-27 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |